Search

Pharming Group NV

Aperta

1.162 1.93

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.1320000000000001

Massimo

1.181

Metriche Chiave

By Trading Economics

Entrata

19M

4.7M

Vendite

14M

93M

EPS

0.006

Margine di Profitto

5.035

Dipendenti

404

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+114.82% upside

Dividendi

By Dow Jones

Utili prossimi

6 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

210M

828M

Apertura precedente

-0.77

Chiusura precedente

1.162

Pharming Group NV Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

23 ott 2025, 20:49 UTC

Utili

Correction to Thermo Fisher Article on Oct. 22

23 ott 2025, 23:51 UTC

Discorsi di Mercato

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23 ott 2025, 23:49 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

23 ott 2025, 23:49 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23 ott 2025, 23:37 UTC

Discorsi di Mercato

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23 ott 2025, 22:58 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

23 ott 2025, 22:57 UTC

Discorsi di Mercato

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23 ott 2025, 22:49 UTC

Acquisizioni, Fusioni, Takeovers

How Trump Sparked a New Era of State Capitalism -2-

23 ott 2025, 22:49 UTC

Acquisizioni, Fusioni, Takeovers

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23 ott 2025, 22:17 UTC

Utili

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23 ott 2025, 21:41 UTC

Utili

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23 ott 2025, 21:05 UTC

Utili

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23 ott 2025, 20:50 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

23 ott 2025, 20:50 UTC

Discorsi di Mercato
Utili

Auto & Transport Roundup: Market Talk

23 ott 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

23 ott 2025, 20:35 UTC

Utili

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23 ott 2025, 20:28 UTC

Utili

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23 ott 2025, 20:15 UTC

Discorsi di Mercato
Utili

Global Commodities Roundup: Market Talk

23 ott 2025, 20:10 UTC

Utili

Newmont Mining 3Q Adj EPS $1.71

23 ott 2025, 20:10 UTC

Utili

Newmont Mining 3Q Sales $5.52B

23 ott 2025, 20:10 UTC

Utili

Newmont Mining 3Q EPS $1.67

23 ott 2025, 20:09 UTC

Utili

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23 ott 2025, 20:07 UTC

Discorsi di Mercato
Utili

Global Equities Roundup: Market Talk

23 ott 2025, 20:07 UTC

Discorsi di Mercato
Utili

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23 ott 2025, 20:07 UTC

Utili

Blackstone Looks to IPOs for Investment Exits -- Update

23 ott 2025, 20:05 UTC

Utili

Intel 3Q Gross Margin 38.2% >INTC

23 ott 2025, 20:04 UTC

Utili

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23 ott 2025, 20:04 UTC

Utili

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23 ott 2025, 20:04 UTC

Utili

Intel: 4Q Guidance Excludes Altera >INTC

23 ott 2025, 20:04 UTC

Utili

Intel Sees 4Q Adj EPS 8c >INTC

Pharming Group NV Previsione

Obiettivo di Prezzo

By TipRanks

114.82% in crescita

Previsioni per 12 mesi

Media 2.449 EUR  114.82%

Alto 2.45 EUR

Basso 2.45 EUR

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Pharming Group NV - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

1 ratings

1

Acquista

0

Mantieni

0

Vendi

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
help-icon Live chat